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Abstract 
Breast cancer chemotherapy can cause side effects due to nonspecific drug delivery, low solubility 
and fast metabolism of drugs used in conventional therapy. Moreover, the therapeutic effect of the 
drugs is often reduced by the strengthening of chemoresistance, which occurs via a variety of 
mechanisms. Different strategies have been developed to reduce multidrug resistance (MDR)-
associated gene expressions including the use of surfactants and polymers. In this study 
superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with conjugated linoleic acid 
(CLA) reduced the number and viability of cells in comparison with both untreated cells or cells 
treated with SPIONs alone. This cytostatic effect correlated with the increase of peroxisome 
proliferator-activated receptors γ (PPARγ). The necrotic cell death induced, as a consequence, an 
inflammatory process, as evidenced by the decrease of the anti-inflammatory PPARα and increase 
of pro-inflammatory TNFα and IL-1β. PPARs were examined because CLA is one of their natural 
ligands. The antitumor effect observed was accompanied by a down-regulation of p-glycoprotein 
(P-gp), which was the first important discovered efflux transporter belonging to MDR, and of 
ALDH3A1, an enzyme able to metabolize some drugs, reducing their effects. The down-regulation 
of P-gp correlated with the increase of cytokines. The ALDH3A1 decrease correlated with the 
increase of PPARγ. Based on these results, PPARs are molecular mediators of anti-cancer effect of 
SPIONs functionalized with CLA, being changes in these nuclear receptors correlated with 
induction of cytotoxicity and inflammation, and decreased ability of cancer cells in blocking anti-
cancer drug effect. 
 
 
Highlights 
 
1. SPIONs+CLA reduce cell number and induce necrotic cell death in mouse breast 4T1 cells. 
2. The decreased cell proliferation correlates with PPARγ increase. 
3. SPIONs+CLA increase pro-inflammatory cytokines correlated with PPARα and P-gp decrease. 
4. The increase of PPARγ also correlates with the decrease of ALDH3A1. 
5. CLA functionalization of SPIONs may ameliorate the anti-cancer potential of nanoparticles 
through PPARs. 
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1. Introduction 
 
Breast cancer is the most common neoplasm, among all cancer types affecting females. It 
represents 25% of all cancer cases and the leading cause of cancer mortality (15%). The number of 
those who die of this neoplasm remains high, even if in the last years screening, early diagnosis and 
improved therapeutic protocols contributed to a fall in total cancer mortality, with a favourable 
trend also for breast cancer [1]. 
Conventional chemotherapy for breast cancer can cause severe side effects due to 
distribution to off-target tissues [2,3]. Moreover, the therapeutic potential of these drugs is often 
reduced by the onset of chemoresistance that occurs in a variety of distinct mechanisms and 
pathways. These include a reduction of intracellular pro-drug activation and an increased drug 
inactivation by Phase I and/or II enzymes [4]. 
In order to overcome the critical aspects of conventional chemotherapy, new 
nanotechnology-based approaches are currently under investigation. In particular, different types of 
nanocarriers, including polymeric nanoparticles, liposomes, micelles and magnetic nanoparticles 
were experimentally tested for cancer diagnosis, imaging and treatment [5]. In particular, 
superparamagnetic iron oxide nanoparticles (SPIONs) have been proposed for diagnostic assays, for 
local hyperthermia-based cancer therapy and intra-tumour delivery of conventional drugs or 
monoclonal antibodies, viral vectors engineered with genes or shRNAs [6–8]. Due to the chance of 
targeting tumor with SPIONs, their side effects on non-cancerous tissues can be reduced [9]. 
Physico-chemical and biological properties of SPIONs can be improved through surface 
modifications, increasing also the nanoparticle dispersion [10,11]. Our previous study highlighted 
that SPIONs functionalized with CLA, known for its anticancer properties, have an increased 
dispersion and a stronger cytotoxic effect on mouse breast cancer cells 4T1 in comparison with 
SPIONs alone [12]. 
In the present study, the mechanisms underlying the effect of CLA-functionalized SPIONs 
(SPIONs+CLA) were investigated. Particular attention was paid to the type of cell death induced, to 
the effect on inflammation process, to the possible involvement of PPARs and to the effect on P-gp 
and ALDH3A1 which are involved in cancer chemoresistance. PPARs were investigated because 
CLA is a natural ligand of these nuclear hormone receptors that regulate the expression of genes 
involved in several intracellular signal transduction pathways, including proliferation and survival. 
 
 
 
2. Materials and Methods 
 
2.1 Materials  
Unless otherwise specified reagents were purchased from Sigma-Aldrich, Germany 
 
2.2 SPION preparation 
Synthesis and characterization of SPIONs were carried out as previously described [12]. In the 
experiments reported here SPIONs alone and SPIONs coated with a single layer of CLA, at the 
highest of the two amounts that were initially synthetized (4.5 µl CLA/ml of SPION suspension, 
SPIONs+CLA), were used for cell treatment. 
 
2.3 Cell Cultures and Treatment of cells with SPIONs 
Mouse breast cancer cells 4T1 were seeded (12,500 cells/cm2) in DMEM/F-12 medium 
supplemented with 2 mM glutamine, 1% (v/v) antibiotic/antimycotic solution, 10% (v/v) fetal 
bovine serum (FBS) and maintained at 37 °C in a humidified atmosphere of 5% CO2 in air. 
24 hours after cell seeding, culture medium was removed and replaced with the same amount of 
medium not supplemented or supplemented with SPIONs or SPIONs+CLA, both at the 
concentrations of 8 μg, 16 μg or 32 μg SPION/105 cells. Untreated 4T1 cells were used as control. 
Human lung A427 cells (ATCC, MD, USA) were cultured (20,000 cells/cm2) in DMEM/F12 
medium supplemented with 2 mM glutamine, 1 % antibiotic/antimycotic solution and 10 % FBS 
A549 human lung-adenocarcinoma cells were from ATCC (Rockville, MD, USA) and cultured 
(25,000 cm−2) in HAM F-12K medium supplemented with 2 mM glutamine, 1% 
antibiotic/antimycotic solution, 1% non-essential amino acids and 10% (v/v) FBS. 
24 hours after cell seeding, culture medium was removed and replaced with the same amount of 
medium not supplemented or supplemented with SPIONs or SPIONs+CLA 16 μg SPION/105 cells. 
 
2.4 Cell growth and viability 
At the different experimental times (12, 24, 48 or 72 h) 4T1 adherent cells were detached by 
trypsin/EDTA (0.5%/0.03 mM), and culture media were collected. Aliquots of both adherent cells 
and culture medium were used for counting cells by flow cytometry analysis.  
Remaining cells and culture medium were combined, centrifuged at 400 g at 4°C for 5 minutes, 
washed with PBS, and resuspended in Annexin-binding buffer (0.5x106 cells/ml) in order to 
evaluate the percentage of viable, necrotic or apoptotic cells by flow cytometry (Annexin V–FITC 
Apoptosis Detection Kit, eBioscience, CA). Briefly, 195 μl of cell suspension were added with 5 μl 
of Annexin V-FITC and incubated at room temperature for 10 min. Then, cells were washed with 
200 μl of binding buffer (1X), resuspended in 190 μl of the same buffer, and added with 10 μl 
(20µg/ml) of propidium iodide. Samples were analysed (20,000 events) by flow cytometry (BD 
Accurri C6, BD Biosciences, CA).  
A549 and A427 cells were detached by trypsin/EDTA (0.5%/0.03 mM) at 72 h and used for growth 
evaluation only. 
 
2.5 Inhibition of PPAR by antagonist GW9662 
Mouse breast cancer cells 4T1 treated as reported in section 2.3 were also supplemented with 10 
μM GW9662, a well known PPAR antagonist. In these experiments the following groups were 
analysed: C, untreated cells; C + Gw9662, untreated cells exposed to 10 M GW9662; M, cells 
treated with SPIONs (16 g/105 cells); M + GW9662, cells treated with SPIONs (16 g/105 cells) + 
10 M GW9662; M + CLA, cells treated with SPIONs + CLA (16 g/105 cells); M + CLA + 
GW9662, cells treated with SPIONs + CLA (16 g/105 cells) + 10 M GW9662. GW9862 was 
added to cell cultures simultaneously with SPIONs. The evaluation of cell growth was carried out at 
24 and 48 h treatment. 
 
2.6 Western Blot and Real-time PCR analyses 
Proteins and total RNA were isolated from 4T1 cells using the Tri-Reagent Kit according to the 
manufacturer's protocol. 
35 µg of proteins were separated by SDS–polyacrylamide gel electrophoresis and electro-
transferred to a polyvinylidene difluoride (PVDF) membrane (Thermo Fisher Scientific, MA), 
which was then blocked for 1 hour with TBS containing 5% non-fat dry milk. The membrane was 
then rinsed and incubated overnight with polyclonal anti-PPARα or anti-PPARγ antibodies (Santa-
Cruz Biotechnology Inc., CA) and monoclonal anti-β-actin antibodies. Protein bands were 
visualized using a chemiluminescent detection system (Pierce® ECL Plus Western Blotting 
Substrate, Thermo Scientific, IL) 
1 μg of total RNA was reverse transcribed to cDNA using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, CA). 16 l of a PCR mixture containing 2 μl of cDNA 
template, 5 pmoles each of forward and reverse primers (Table 1), bidistilled water and the 
Power SYBR® Green PCR Master Mix (Applied Biosystems, CA) were amplified using an iCycler 
PCR instrument (Bio-Rad, CA) with an initial denaturation at 95 °C for 10 min, followed by 35–40 
cycles at 95 °C for 30 s, annealing at 52 °C for 40 s, extension at 72°C for 40 s. Each sample was 
tested in duplicate and threshold cycle (Ct) values were averaged out from each reaction. The 
change in expression was defined as that detected in the treated 4T1 cells versus that detected in the 
untreated cells, calculated as 2-ΔΔCt, where ΔCt=Ctsample-CtGAPDH and ΔΔCt=ΔCtsample-ΔCtcontrol. 
 
2.7 Protein content determination 
Protein content was measured using the DCTM Protein Assay Kit, following the manufacturer's 
instructions (Bio-Rad Laboratories Inc., CA). 
 
2.8 Pro-inflammatory cytokine protein content 
TNFα and IL-1 content was evaluated in the culture medium by Enzyme Linked Immuno Sorbent 
Assay (Invitrogen Corporation, Frederick, MD). 
 
2.9 Statistical Analysis 
All data were expressed as means ± SD. Differences between group means were assessed by 
analysis of variance followed by the post hoc Newman–Keuls test. 
 
 
 
3. Results 
 
Mouse breast cancer 4T1 cells were exposed to 8, 16 or 32 µg/105 cells of SPIONs or 
SPIONs+CLA and the variations in cell number were recorded for up to 72 hours as reported in 
Figure 1. All the concentrations of both types of nanoparticles caused a reduction of cell number in 
comparison with control cells. Regarding the two treatments, the biggest effect was observed in 
presence of SPIONs+CLA. The reduction of cell number with this SPIONs was dose-dependent 
until 48 hours after the treatment, reaching the major reduction at 48 h with 32 g/105 cells (55.2 
%). Results at 72 hours evidenced that the numbers of cells were similar to those observed at 48 
hours for 8 and 16 g/105 cells, whereas for 32 g/105 cells a growth recovery was observed. 
The flow cytometry analysis of viability and of type of cell death is reported in Figure 2. 
The results evidenced that both treatments induced necrosis and a few apoptosis, but the cytotoxic 
effect induced by SPIONs+CLA was bigger. The cytotoxic effect is dose-dependent until 48 h of 
treatment, whereas at 72 h the cells were more viable than after 48 h, being the increase of viable 
cells about 11% in presence of SPIONs+CLA 8 and 16 g/105 cells and 18% in case of 
SPIONs+CLA 32 g/105 cells. It is important to underline that functionalization with CLA 
increased the cytotoxic effect of SPIONs alone of about 100%.  
 Table 2 reports data relative to the effect of SPIONs functionalized or not with CLA on 
human lung cancer cells A549 and A427., showing that CLA presence induced a higher inhibition 
of cell growth in more malignant A427 cells than in less malignant A549. 
Since CLA is a ligand of PPARs, as other polyunsaturated fatty acids, PPARγ protein 
content was evaluated. Figure 3 shows an increase of PPARγ at 24 h in cells treated with both 
SPIONs in comparison with the control cells, the increase being bigger in cells treated with 
SPIONs+CLA and consistent with the reduction of cell number and cell toxicity.  
The involvement of PPAR in reducing 4T1 cell growth has been investigated using 
GW9662, a well known antagonist of this nuclear receptor. Results reported in Table 3 evidenced 
that the inhibition of PPAR by GW9662 always increased the cell numbers, being the major 
recovery present in case of SPIONs + CLA. 
The presence of cell necrosis suggested to evaluate some inflammation-related parameters: 
PPARα, TNFα and IL-1β at the experimental time of 72 h. Figure 4 shows that PPARα protein 
content decreased with both types of SPIONs and, again, the highest decrease was observed in cells 
treated with SPIONs+CLA in comparison with SPIONs alone and control cells. The decrease of 
PPARα was accompanied by the increase of cytokine protein content, like other parameters 
examined, i.e. there was a bigger increase in cells treated with SPIONs+CLA in comparison with 
SPIONs alone and control cells.  
P-gp and ALDH3A1 were evaluated in order to investigate the effect of these types of 
SPIONs on the mechanism involved in cancer chemoresistance. Figure 5 shows a decrease of P-gp 
and ALDH3A1 in 4T1 cells treated with both types of SPIONs, being SPIONs+CLA the most 
efficient in the decrease.  
 
 
4. Discussion 
 
In a previous study we evidenced that SPIONs functionalized with CLA affected viability of 
4T1 breast cancer cells, being the effect observed bigger if compared to SPIONs alone. This effect 
is due to the increased colloidal stability and the anti-cancer properties of the CLA [13]. 
In this study we investigated the molecular pathways triggered by SPIONs+CLA, paying 
particular attention to the effect on cell proliferation and cell death. Moreover, to confirm the ability 
of SPIONs in reducing cancer cell growth, their effect has been investigated in a preliminary way in 
human lung cancer cells. The flow cytometry analysis on 4T1 breast cancer cells evidenced that the 
decreased cell viability was mainly due to the induction of necrotic cell death, while the percentage 
of the apoptotic cells was close to 0 %. The decreased efficacy of SPIONs + CLA in reducing cell 
growth observed at 72 h could be the consequence of CLA intracellular metabolism, leading to a 
decrease of intracellular free CLA able to trigger signal transduction pathways.  
Interestingly, results on human lung cancer cells seemed to indicate that SPIONs + CLA 
show a major effect on more malignant cell line. 
The decreased cell number seems negatively correlated with the increased level of PPARγ 
after 24 h from treatment. This result agrees with what observed in different tumour cell lines 
treated with CLA, where the decreased cell proliferation associated with the increase of PPARγ 
level [14]. With regard to the present study, the pivotal role played by this nuclear receptor in 
modulating SPIONs cytostatic effect has been evidenced by the observation that the antagonist 
GW9662 completely reversed the decrease of cell number. Moreover, the increased cell number 
occurring in control cells treated with GW9662 alone further confirm the inverse correlation 
between PPAR and proliferation. 
Concerning the absence of the apoptotic process, this may partially be the consequence of 
the non-increasing PPARα levels. In fact, a previous study with SK-HEP-1 cells, a human 
hepatocarcinatoma cell line, showed that CLA-induced apoptosis was associated with an increase in 
PPARα protein. Meanwhile in MDA-MB-231, a human breast cancer cell line, the CLA-induced 
inhibition of cell proliferation was not associated with apoptosis and was not accompanied by an 
increased content of PPARα protein [14,15]. 
The evident necrotic process focused our attention on the resulting inflammation induction. 
The analysis of some of the parameters involved in the inflammatory process evidenced an increase 
in pro-inflammatory cytokines TNFα and IL-1β. This increase inversely correlates with the 
decreased level of PPARα. These results confirm what was previously seen in human lung 
adenocarcinoma A427 cells treated with CLA [16]. 
An important characteristic of tumor cells is their ability to block the effect of drugs, 
developing resistance by different mechanisms. One possibility is represented by the alterations of 
the efflux transporters such as P-gp [17], while, another one, is to metabolize the drug, making it 
inactive.  
 The acquired resistance to drugs (MDR) could be due to copy number alterations or 
increased expression of different genes [16] and is an important impediment for successful 
chemotherapy [18,19]. The most important and well-studied MDR-genes are: ABCB 1 that encodes 
the P-glycoprotein (P-gp), the multidrug resistance protein 1 (MDR1), ABCC 1–3 that encodes the 
multi-drug resistance associated protein (MRP) 1–3 and ABCG 2 encoding the breast cancer 
resistance protein (BCRP). Different strategies were developed to reduce MDR-associated gene 
expressions including the use of surfactants that inhibit the drug-efflux and polymers for their 
ability to improve the intracellular transport of chemotherapeutics [16]. Recently, different studies 
have evaluated the capability of various nanoparticle formulation in overcoming MDR in breast 
cancer, showing that drugs encapsulated by nanomaterials enter the cancer cells through different 
mechanisms overcoming the drug transporters and reversing MDR [17]. 
P-gp was one of the first efflux transporter discovered [20–22]; it provides, in physiological 
conditions, protection from xenobiotics during brain development and it was highlighted to be up-
regulated by glucocorticoids and inhibited by pro-inflammatory cytokines [22]. In different “in 
vivo” and “in vitro” liver and colon tumor models TNFα downregulated ABCB 1 expression, 
causing a reduction of drug efflux and an increase of cytotoxicity [23,24]. This correlation was 
confirmed also in this study where the functionalization with CLA increased the production of 
TNFα and IL-1β and decreased the expression of P-gp in comparison with control cells and cells 
treated with SPIONs alone. 
The ability of cancer cells to block the effect of drugs is also due to the increased expression of 
ALDH3A1. SPIONs + CLA reduced the expression of ALDH3A1 through the increase of PPARγ. 
This inverse correlation between ALDH3A1 and PPARγ was shown in our previous study on 
human lung tumor A549 cells where the ALDH3A1 expression was decreased by arachidonic acid, 
another ligand of PPARs, via the activation of PPARγ and the consequent inhibition of NF-κB 
transcriptional activity. In fact, ALDH3A1 gene possesses several NF-κB binding sites [25,26] 
which are involved in the positive and negative regulation of its expression [27]. 
 
 
5. Conclusions 
 
 This research demonstrated the SPIONs functionalized with CLA are able to reduce cell 
number, induce necrotic cell death and inflammation in mouse breast 4T1 cells. These effects are 
mediated by PPARs: the increase of PPARγ correlated with the decreased cell proliferation and the 
decrease of PPARα with the increase of pro-inflammatory cytokines. In turn, this increase is 
responsible for the decrease of P-gp mRNA level. The increase of PPARγ also correlates with the 
decrease of ALDH3A1.   
 The study results indicate that the anti-cancer properties of SPIONs functionalized with 
CLA are mediated by PPARs, being changes in these nuclear receptors correlated with induction of 
cytotoxicity and inflammation, and decreased ability of cancer cells in blocking anticancer drug 
effect. 
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Figure Captions 
 
Figure 1. Number of mouse breast cancer 4T1 cells untreated or treated with SPIONs functionalized 
or not with CLA. 
The number of cells is expressed as percentage of untreated cells set equal to 100 %. The values are 
means ± S.D. of 4 experiments. For each group (SPIONs or SPIONs+CLA) means with different 
letters are significantly different from one another (p<0.05) as determined by analysis of variance 
followed by a post-hoc Newman-Keuls test. 
SPIONs: cells treated with superparamagnetic iron oxide nanoparticles; SPIONs+CLA: cells treated 
with superparamagnetic iron oxide nanoparticles functionalized with conjugated linoleic acid; CLA: 
conjugated linoleic acid; C: untreated cells (black line); 8 µg, 16 µg, 32 µg quantity of various 
SPIONs added to 100,000 cells. 
 
Figure 2. Viability of mouse breast cancer 4T1 cells untreated or treated with SPIONs 
functionalized or not with CLA. 
Data are means ± S.D. of 4 experiments and indicate the percentage of cells that are viable, in 
apoptosis or in necrosis vs. the total number of cells analyzed by flow cytometry, taken as 100%. 
SD, not reported, is less than 10% in all cases. For each experimental time analyzed (12, 24, 48 or 
72 h), means with different letters are significantly different from one another (p<0.05) as 
determined by analysis of variance followed by a post-hoc Newman-Keuls test. 
SPIONS: cells treated with superparamagnetic iron oxide nanoparticles; SPIONs+CLA: cells 
treated with superparamagnetic iron oxide nanoparticles functionalized with conjugated linoleic 
acid; CLA: conjugated linoleic acid; C: untreated cells; 8 µg, 16 µg, 32 µg: quantity of various 
SPIONs added to 100,000 cells. 
 
Figure 3. PPARγ protein content in mouse breast cancer 4T1 cells untreated or treated with SPIONs 
functionalized or not with CLA. 
The protein content was determined by Western blot analysis. Band intensities were normalized to 
the corresponding β-actin value and expressed as a percentage, setting the value of untreated cells 
(C) arbitrarily at 100%. Data are means ± S.D. of 4 experiments. For each experimental time 
considered (24 or 72 h), means with different letters are significantly different from one another 
(p<0.05) as determined by analysis of variance followed by a post-hoc Newman-Keuls test. 
See legend in Fig. 2 for acronyms. 
 
Figure 4. PPARα, TNFα and IL-1β protein content evaluated after 72 h treatment in mouse breast 
cancer 4T1 cells untreated or treated with SPIONs functionalized or not with CLA. 
The PPARγ protein content was determined by Western blot analysis. Band intensities were 
normalized to the corresponding β-actin value and expressed as a percentage, setting the value of 
untreated cells (C) arbitrarily at 100%. 
TNFα and IL-1β release, determined by ELISA assay, was expressed as % of untreated cells set 
equal to 100 %.  
Data are means ± S.D. of 4 experiments. For each protein (PPARα, TNFα or IL-1β) means with 
different letters are significantly different from one another (p<0.05) as determined by analysis of 
variance followed by a post-hoc Newman-Keuls test. 
See legend in Fig. 2 for acronyms. 
 
Figure 5. P-glycoprotein and ALDH3A1. mRNA content evaluated after 72 h in mouse breast 
cancer 4T1 cells untreated or treated with SPIONs functionalized or not with CLA. 
The mRNA, determined by real time PCR, was expressed as % of untreated cells set equal to 100 
%. Data are means ± S.D. of 4 experiments. Means with different letters are significantly different 
from one another (p<0.05) as determined by analysis of variance followed by a post-hoc Newman-
Keuls test. 
See legend in Fig. 1 for acronyms. 
 
